SCHEMBL201194

SCHEMBL201194

COC(=O)[C@@H]1C[C@](O)(CO)CN1C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
MITF O75030 1/20 0.47
MAPT P10636 1/20 0.47
HTR2C P28335 1/20 0.44
FKBP1A P62942 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PREP P48147 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
CYP3A4 P08684 1/20 0.42
CASP1 P29466 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201195 1.00 HTT (0.47) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL9977347 1.00 HTT (0.47) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL203202 0.91 HTT (0.49) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL203203 0.91 HTT (0.49) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL31376851 0.87 MITF (0.44) HTTMITFMAPTFKBP1ANPSR1
SCHEMBL18020339 0.85 MITF (0.49) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL8279227 0.84 MITF (0.48) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL4849095 0.84 HTT (0.48) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL8298601 0.84 MITF (0.48) HTTMITFMAPTHTR2CFKBP1A
SCHEMBL4849092 0.84 HTT (0.48) HTTMITFMAPTHTR2CFKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HTT 434/4885MITF 1897/4885MAPT 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.